Mitogen-activated protein kinase kinase (MAP2K; MEK; MAPKK) inhibitors have been reported in an Immuneering Corp. patent as potentially useful for the treatment of cancer.
Guangzhou Kaishi Pharmaceutical Co. Ltd. has patented treprostinil derivatives acting as nitric oxide (NO) donors reported to be useful for the treatment of acute respiratory distress syndrome, pulmonary arterial hypertension and arterial occlusion.
Recludix Pharma Inc. has disclosed signal transducer and activator of transcription 3 (STAT3) and/or STAT6 inhibitors reported to be useful for the treatment of cancer and inflammatory disorders.
Bright Minds Biosciences Inc. has created phenethlyamines acting as 5-HT2A receptor agonists and reported to be useful for the treatment of depression and anxiety disorders.
Research at Beigene Co. Ltd. has led to the identification of new proteolysis targeting chimera (PROTAC) compounds comprising E3 ubiquitin ligase binding moiety covalently linked to a Bruton tyrosine kinase (BTK) targeting moiety via linker. They are reported to be useful for the treatment of cancer.
Heteroaryl compounds acting as interleukin-1 receptor-associated kinase 4 (IRAK-4) inhibitors are described in a recent Accro Bioscience (HK) Ltd. patent. They are reported to be useful for the treatment of endometriosis, systemic lupus erythematosus, multiple sclerosis, psoriasis, rheumatoid arthritis, primary central nervous system and diffuse large B-cell lymphoma.
Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have jointly patented tricyclic compounds acting as mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1) inhibitors. As such, they are reported to be useful for the treatment of cancer and autoimmune diseases.
JS Innomed Holdings Ltd. and JS Innopharm Ltd. have developed new tyrosine-protein phosphatase non-receptor type 11 (PTPN11; PTP-2C; SHP-2) inhibitors reported to be useful for the treatment of cancer, LEOPARD syndrome and Noonan syndrome.
Indazole compounds acting as microsomal prostaglandin E2 synthase-1 (mPGES-1) inhibitors have been described in a recent Nippon Shinyaku Co. Ltd. patent as potentially useful for the treatment of irritable bowel syndrome, psoriasis, arthritis, bacterial infection, systemic lupus erythematosus, pancreatitis, asthma and chronic obstructive pulmonary disease, among others.
RSS